1. Lymphocytosis, Neutrophil/Lymphocyte Ratio and Monocyte/Lymphocyte Ratio as Prognostic Markers in CMML. (April 2017) Authors: Silzle, T.; Schuler, E.; Hildebrandt, B.; Haas, R.; Templeton, A.; Germing, U. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1053: ALBUMIN AND C-REACTIVE PROTEIN PROVIDE PROGNOSTIC INFORMATION INDEPENDENTLY FROM MIPSS70 IN OVERT MYELOFIBROSIS. A RETROSPECTIVE STUDY. (23rd June 2022) Authors: Messerich, N.-M.; Volken, T.; Cogliatti, S.; Lehmann, T.; Holbro, A.; Demmer, I.; Benz, R.; Jochum, W.; Silzle, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 943 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. (23rd June 2022) Authors: Koster, K.-L.; Messerich, N.-M.; Volken, T.; Cogliatti, S.; Lehmann, T.; Holbro, A.; Benz, R.; Graf, L.; Demmer, I.; Jochum, W.; Silzle, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The Swiss MDS Registry/Biobank: Interim-Report of Pilot Phase from a Cooperative Research Platform for Personalized Medicine in Hemato-Oncology in Switzerland. (April 2017) Authors: Bonadies, N.; Bacher, V.U.; Rovo, A.; Bohlius, J.; Stüssi, G.; Gerber, B.; Wilk, C.; Balabanov, S.; Ruefer, A.; Benz, R.; Holbro, A.; Cantoni, N.; Schmid, M.; Mengis-Bay, C.; Blum, S.; Silzle, T.; Lehmann, T.; Goede, J. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY. (September 2021) Authors: Silzle, T.; Taylor, A.; De Witte, T.; Malcovati, L.; Fenaux, P.; Bowen, D.; Symeonidis, A.; Mittelman, M.; Stauder, R.; Cermak, J.; Sanz, G.; Hellström-Lindberg, E.; Langemeijer, S.; Holm, M. Skov; Madry, K.; Tatic, A.; Almeida, A. Medina; Savic, A.; Rogulj, I. Mandac; Germing, U. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗